S&P 500   4,231.62 (+1.24%)
DOW   33,161.35 (+0.77%)
QQQ   352.62 (+1.33%)
AAPL   179.99 (+1.55%)
MSFT   332.75 (+1.33%)
META   273.50 (+3.32%)
GOOGL   123.46 (+0.48%)
AMZN   122.91 (+1.93%)
TSLA   208.97 (+2.47%)
NVDA   399.04 (+5.47%)
NIO   7.60 (+0.93%)
BABA   83.30 (+4.71%)
AMD   120.43 (+1.88%)
T   15.83 (+0.64%)
F   12.11 (+0.92%)
MU   69.20 (+1.47%)
CGC   0.83 (-0.44%)
GE   104.89 (+3.31%)
DIS   88.67 (+0.81%)
AMC   4.59 (+2.00%)
PFE   37.97 (-0.13%)
PYPL   63.21 (+1.97%)
NFLX   404.87 (+2.44%)
S&P 500   4,231.62 (+1.24%)
DOW   33,161.35 (+0.77%)
QQQ   352.62 (+1.33%)
AAPL   179.99 (+1.55%)
MSFT   332.75 (+1.33%)
META   273.50 (+3.32%)
GOOGL   123.46 (+0.48%)
AMZN   122.91 (+1.93%)
TSLA   208.97 (+2.47%)
NVDA   399.04 (+5.47%)
NIO   7.60 (+0.93%)
BABA   83.30 (+4.71%)
AMD   120.43 (+1.88%)
T   15.83 (+0.64%)
F   12.11 (+0.92%)
MU   69.20 (+1.47%)
CGC   0.83 (-0.44%)
GE   104.89 (+3.31%)
DIS   88.67 (+0.81%)
AMC   4.59 (+2.00%)
PFE   37.97 (-0.13%)
PYPL   63.21 (+1.97%)
NFLX   404.87 (+2.44%)
S&P 500   4,231.62 (+1.24%)
DOW   33,161.35 (+0.77%)
QQQ   352.62 (+1.33%)
AAPL   179.99 (+1.55%)
MSFT   332.75 (+1.33%)
META   273.50 (+3.32%)
GOOGL   123.46 (+0.48%)
AMZN   122.91 (+1.93%)
TSLA   208.97 (+2.47%)
NVDA   399.04 (+5.47%)
NIO   7.60 (+0.93%)
BABA   83.30 (+4.71%)
AMD   120.43 (+1.88%)
T   15.83 (+0.64%)
F   12.11 (+0.92%)
MU   69.20 (+1.47%)
CGC   0.83 (-0.44%)
GE   104.89 (+3.31%)
DIS   88.67 (+0.81%)
AMC   4.59 (+2.00%)
PFE   37.97 (-0.13%)
PYPL   63.21 (+1.97%)
NFLX   404.87 (+2.44%)
S&P 500   4,231.62 (+1.24%)
DOW   33,161.35 (+0.77%)
QQQ   352.62 (+1.33%)
AAPL   179.99 (+1.55%)
MSFT   332.75 (+1.33%)
META   273.50 (+3.32%)
GOOGL   123.46 (+0.48%)
AMZN   122.91 (+1.93%)
TSLA   208.97 (+2.47%)
NVDA   399.04 (+5.47%)
NIO   7.60 (+0.93%)
BABA   83.30 (+4.71%)
AMD   120.43 (+1.88%)
T   15.83 (+0.64%)
F   12.11 (+0.92%)
MU   69.20 (+1.47%)
CGC   0.83 (-0.44%)
GE   104.89 (+3.31%)
DIS   88.67 (+0.81%)
AMC   4.59 (+2.00%)
PFE   37.97 (-0.13%)
PYPL   63.21 (+1.97%)
NFLX   404.87 (+2.44%)
NASDAQ:AGEN

Agenus (AGEN) Stock Forecast, Price & News

$1.59
+0.03 (+1.92%)
(As of 02:51 PM ET)
Compare
Today's Range
$1.49
$1.63
50-Day Range
$1.31
$1.80
52-Week Range
$1.25
$3.37
Volume
2.08 million shs
Average Volume
4.76 million shs
Market Capitalization
$554.72 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$7.33

Agenus MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
359.2% Upside
$7.33 Price Target
Short Interest
Bearish
5.74% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-0.93
Upright™ Environmental Score
News Sentiment
0.35mentions of Agenus in the last 14 days
Based on 3 Articles This Week
Insider Trading
Acquiring Shares
$267,492 Bought Last Quarter
Proj. Earnings Growth
Growing
From ($0.81) to ($0.74) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.27 out of 5 stars

Medical Sector

655th out of 1,980 stocks

Biological Products, Except Diagnostic Industry

89th out of 330 stocks


AGEN stock logo

About Agenus (NASDAQ:AGEN) Stock

Agenus, Inc. is a clinical-stage company, which engages in the development and commercialization of technologies to treat cancers and infectious diseases. Its product pipeline includes Balstilimab, Zalifrelimab, AGEN1181, AGEN1327, AGEN2373, AGENt-797 and AGEN1777. The company was founded by Garo H. Armen and Pramod K. Srivastava on March 31, 1994 and is headquartered in Lexington, MA.

Receive AGEN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Agenus and its competitors with MarketBeat's FREE daily newsletter.

AGEN Stock News Headlines

Graphite Shortage Could Derail the $7 Trillion EV Transition
Graphite (not lithium) is expected to see the largest increase in demand of all battery metals over the next decade. But projections warn of an 8 million ton shortfall of graphite by 2040. That's why 97 more graphite mines are needed just to keep up with battery production for the $7 trillion transition to electric vehicles.
Agenus (NASDAQ:AGEN) Coverage Initiated at StockNews.com
ChatGPT Is Already "Old School"
As good as ChatGPT is at writing content, it still doesn't understand what it's saying. But a new AI technology breakthrough will understand and process information like a human. One young company is leading the way.
H.C. Wainwright Reaffirms Their Buy Rating on Agenus (AGEN)
Agenus (AGEN) Q1 2023 Earnings Call Transcript
Agenus (NASDAQ:AGEN) Shares Up 4%
Analysts Set Agenus Inc. (NASDAQ:AGEN) Price Target at $7.33
Agenus to Participate in May Investor Conferences
B.Riley Financial Sticks to Its Buy Rating for Agenus (AGEN)
Short Interest in Agenus Inc. (NASDAQ:AGEN) Grows By 16.4%
See More Headlines

AGEN Price History

AGEN Company Calendar

Last Earnings
3/14/2023
Today
6/01/2023
Next Earnings (Estimated)
8/08/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Biological products, except diagnostic
Sub-Industry
Biotechnology
Sector
Medical
Current Symbol
NASDAQ:AGEN
CUSIP
00847G70
Employees
441
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$7.33
High Stock Price Forecast
$8.30
Low Stock Price Forecast
$5.00
Forecasted Upside/Downside
+359.2%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
4 Analysts

Profitability

Net Income
$-220,070,000.00
Net Margins
-264.19%
Pretax Margin
-264.19%

Debt

Sales & Book Value

Annual Sales
$98.02 million
Book Value
($0.15) per share

Miscellaneous

Free Float
332,130,000
Market Cap
$556.46 million
Optionable
Optionable
Beta
1.43

Key Executives

  • Garo H. ArmenGaro H. Armen
    Chairman & Chief Executive Officer
  • Christine M. Klaskin
    Chief Financial & Accounting Officer, VP-Finance
  • Steven O’DaySteven O’Day
    Chief Medical Officer
  • Craig Winter
    Chief Information Officer
  • Alfred Dadson
    Chief Manufacturing Officer













AGEN Stock - Frequently Asked Questions

Should I buy or sell Agenus stock right now?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Agenus in the last twelve months. There are currently 4 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" AGEN shares.
View AGEN analyst ratings
or view top-rated stocks.

What is Agenus' stock price forecast for 2023?

4 Wall Street analysts have issued 1 year price targets for Agenus' stock. Their AGEN share price forecasts range from $5.00 to $8.30. On average, they predict the company's share price to reach $7.33 in the next twelve months. This suggests a possible upside of 359.2% from the stock's current price.
View analysts price targets for AGEN
or view top-rated stocks among Wall Street analysts.

How have AGEN shares performed in 2023?

Agenus' stock was trading at $2.40 on January 1st, 2023. Since then, AGEN stock has decreased by 33.5% and is now trading at $1.5950.
View the best growth stocks for 2023 here
.

When is Agenus' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, August 8th 2023.
View our AGEN earnings forecast
.

How were Agenus' earnings last quarter?

Agenus Inc. (NASDAQ:AGEN) released its quarterly earnings data on Tuesday, March, 14th. The biotechnology company reported ($0.24) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.22) by $0.02. The biotechnology company had revenue of $28.39 million for the quarter, compared to analyst estimates of $17.83 million. Agenus had a negative net margin of 264.19% and a negative trailing twelve-month return on equity of 1,159.04%.

What is Garo H. Armen's approval rating as Agenus' CEO?

2 employees have rated Agenus Chief Executive Officer Garo H. Armen on Glassdoor.com. Garo H. Armen has an approval rating of 56% among the company's employees. This puts Garo H. Armen in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Agenus own?
What is Agenus' stock symbol?

Agenus trades on the NASDAQ under the ticker symbol "AGEN."

Who are Agenus' major shareholders?

Agenus' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include State Street Corp (7.50%), BlackRock Inc. (7.05%), Bank of America Corp DE (2.40%), Geode Capital Management LLC (1.58%), Renaissance Technologies LLC (1.34%) and Charles Schwab Investment Management Inc. (0.64%). Insiders that own company stock include Agenus Inc, Christine M Klaskin, Corp Incyte, Garo H Armen and Steven J O'day.
View institutional ownership trends
.

How do I buy shares of Agenus?

Shares of AGEN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Agenus' stock price today?

One share of AGEN stock can currently be purchased for approximately $1.60.

How much money does Agenus make?

Agenus (NASDAQ:AGEN) has a market capitalization of $556.46 million and generates $98.02 million in revenue each year. The biotechnology company earns $-220,070,000.00 in net income (profit) each year or ($0.82) on an earnings per share basis.

How many employees does Agenus have?

The company employs 441 workers across the globe.

How can I contact Agenus?

Agenus' mailing address is 3 FORBES ROAD, LEXINGTON MA, 02421. The official website for the company is agenusbio.com. The biotechnology company can be reached via phone at (781) 674-4400, via email at investor@agenusbio.com, or via fax at 781-674-4200.

This page (NASDAQ:AGEN) was last updated on 6/1/2023 by MarketBeat.com Staff

My Account -